Bank of America Corp DE Has $6.95 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Bank of America Corp DE decreased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 86.4% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 230,939 shares of the biopharmaceutical company's stock after selling 1,466,433 shares during the period. Bank of America Corp DE owned 0.15% of TG Therapeutics worth $6,951,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Barclays PLC grew its holdings in TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after purchasing an additional 158,323 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in TG Therapeutics by 52.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 8,112 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 2,803 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new stake in TG Therapeutics in the 4th quarter valued at about $228,000. Blue Trust Inc. lifted its position in TG Therapeutics by 105.9% in the 4th quarter. Blue Trust Inc. now owns 3,121 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 1,605 shares during the last quarter. Finally, KBC Group NV increased its stake in TG Therapeutics by 48.9% during the 4th quarter. KBC Group NV now owns 6,960 shares of the biopharmaceutical company's stock valued at $209,000 after buying an additional 2,285 shares during the period. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Performance

TGTX stock traded down $0.31 on Friday, reaching $35.40. 739,370 shares of the company were exchanged, compared to its average volume of 2,965,869. TG Therapeutics, Inc. has a 12 month low of $15.16 and a 12 month high of $46.48. The stock's fifty day moving average price is $37.55 and its 200 day moving average price is $34.40. The firm has a market capitalization of $5.62 billion, a PE ratio of -354.11 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. During the same quarter in the prior year, the company posted ($0.07) EPS. The company's quarterly revenue was up 90.4% compared to the same quarter last year. On average, research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.